© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 18, 1534-1535,
September 20, 2000
© 2000 Oxford University Press
CORRESPONDENCE |
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
Affiliations of authors: I. Vergote, University Hospitals Leuven, Belgium; G. J. Rustin, Mount Vernon Hospital, Northwood, U.K.; E. A. Eisenhauer, National Cancer Institute of Canada, Kingston, Canada; G. B. Kristensen, Norwegian Radium Hospital, Oslo, Norway; E. Pujade-Lauraine, Hospital Hotel Dieu, Paris, France; M. K. Parmar, Medical Research Council, London, U.K.; M. Friedlander, Prince of Wales Hospital, Sydney, Australia; A. Jakobsen, Velje Hospital, Velje, Denmark; J. B. Vermorken, University Hospital Antwerp, Belgium.
Correspondence to: Ignace Vergote, M.D., Ph.D., University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.
We read with much interest the article by Therasse et al. (1) on the new Response Evaluation Criteria in Solid Tumors Group (RECIST) in the Journal. In the RECIST, the definition of progression is based on the evaluation of measurable and nonmeasurable disease. However, it is our experience that, in many randomized trials of the first-line treatment
NOTES
RREFERENCES
Correspondence about this Article
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2004 96: 487-488.
This article has been cited by other articles:
|
|
 |
|
  A. Prat, M. Parera, B. Adamo, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, J. Baselga, and J. M. del Campo Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Ann. Onc., September 26, 2008; (2008) mdn601v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Johnatty, J. Beesley, J. Paul, S. Fereday, A. B. Spurdle, P. M. Webb, K. Byth, S. Marsh, H. McLeod, AOCS Study Group, et al. ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy Clin. Cancer Res., September 1, 2008; 14(17): 5594 - 5601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Tummala and W. P. McGuire Ovarian Cancer, CA-125 Addiction, and Informed Confusion: Much Ado About Less J. Clin. Oncol., August 20, 2007; 25(24): 3570 - 3571. [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Liu, D. S. Alberts, B. J. Monk, M. Brady, J. Moon, and M. Markman An Early Signal of CA-125 Progression for Ovarian Cancer Patients Receiving Maintenance Treatment After Complete Clinical Response to Primary Therapy J. Clin. Oncol., August 20, 2007; 25(24): 3615 - 3620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J-M Ferrero, B Weber, J-F Geay, D Lepille, H Orfeuvre, M Combe, F Mayer, B Leduc, H Bourgeois, D Paraiso, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial Ann. Onc., February 1, 2007; 18(2): 263 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Coleman, A. Gordon, J. Barter, S. Sun, W. Rackoff, and T. J. Herzog Early Changes in CA125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients Oncologist, January 1, 2007; 12(1): 72 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J.S. Rustin, P. Timmers, A. Nelstrop, G. Shreeves, S. M. Bentzen, B. Baron, M. J. Piccart, K. Bertelsen, G. Stuart, J. Cassidy, et al. Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide J. Clin. Oncol., January 1, 2006; 24(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Delord, C. Allal, M. Canal, E. Mery, P. Rochaix, I. Hennebelle, A. Pradines, E. Chatelut, R. Bugat, S. Guichard, et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma Ann. Onc., December 1, 2005; 16(12): 1889 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, S. Miyamoto, S. O. Suzuki, E. Oki, H. Yagi, K. Sonoda, A. Yamazaki, H. Mizushima, Y. Maehara, E. Mekada, et al. Clinical Significance of Heparin-Binding Epidermal Growth Factor-Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4783 - 4792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Crawford and J. Peace Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann. Onc., January 1, 2005; 16(1): 47 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J.S. Rustin Can We Now Agree to Use the Same Definition to Measure Response According to CA-125? J. Clin. Oncol., October 15, 2004; 22(20): 4035 - 4036. [Full Text] [PDF]
|
|
|
|
|
|
G. J. S. Rustin, R. C. Bast Jr., G. J. Kelloff, J. C. Barrett, S. K. Carter, P. D. Nisen, C. C. Sigman, D. R. Parkinson, and R. W. Ruddon Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3919 - 3926. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. S. Rustin, M. Quinn, T. Thigpen, A. du Bois, E. Pujade-Lauraine, A. Jakobsen, E. Eisenhauer, S. Sagae, K. Greven, I. Vergote, et al. Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) J Natl Cancer Inst, March 17, 2004; 96(6): 487 - 488. [Full Text] [PDF]
|
|
|
|
|
|
G. J.S. Rustin Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials J. Clin. Oncol., May 15, 2003; 21(90100): 187s - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.E. Guppy and G.J.S. Rustin CA125 Response: Can it Replace the Traditional Response Criteria in Ovarian Cancer? Oncologist, October 1, 2002; 7(5): 437 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. Hummer, E. Venkatraman, and D. R. Spriggs Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1238 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J.S. Rustin, M. Marples, A. E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels J. Clin. Oncol., October 15, 2001; 19(20): 4054 - 4057. [Abstract] [Full Text] [PDF]
|
|